Article · 22 Sep 2026
Research articlePublished 3 May 2019
Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Undeterred efforts have been made and will be made in future to make it possible for HIV-infected individuals to achieve the goals of virologic suppression and one more addition to this rigorous exercise is dolutegravir drug. It is a recent integrase inhibitor approved by the United States of Food and Drug Administration (USFDA) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of drug including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that may play an important role in the treatment of patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in pipeline which may hope to increase the immunologic response of the HIV patients.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Der Pharma Chemica.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDer Pharma Chemica
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Geeta Yadav”
- BylineArticles whose byline prints “Piyush Kumar”